

# NCTN Breast Cancer Trials Portfolio (Open as of 5/15/2026)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and study information.

Neoadjuvant	Post-Neoadjuvant	Adjuvant	Metastatic
<div data-bbox="142 284 451 479" style="border: 1px solid black; padding: 5px; margin-bottom: 10px;"> <p><b>S2212 (SCARLET)</b> TNBC T2-4/N0/M0, or T1-3/N1-2/M0</p> </div> <div data-bbox="142 527 451 673" style="border: 1px solid black; padding: 5px;"> <p><b>S2206</b> HR+/HER2- Stage II or III</p> </div>	<div data-bbox="550 284 955 503" style="border: 1px solid black; padding: 5px; margin-bottom: 10px;"> <p><b>A012103 (OptimICE-PCR)</b> TNBC Early-Stage, pCR post pre-op chemo + pembrolizumab</p> </div> <div data-bbox="550 548 955 768" style="border: 1px solid black; padding: 5px;"> <p><b>A012303 (ShortStop-HER2)</b> HER2+ Early-Stage, pCR post pre-op chemo + HER2 blockade</p> </div>	<div data-bbox="1050 284 1455 430" style="border: 1px solid black; padding: 5px; margin-bottom: 10px;"> <p><b>CCTG MA.39</b> HR+/HER2- Low risk; Node positive</p> </div> <div data-bbox="1050 475 1455 695" style="border: 1px solid black; padding: 5px;"> <p><b>NRG-BR009 (OFSET)</b> HR+/HER2- pT1-3/N0-1/M0, Oncotype Recurrence Score ≤ 25, Premenopausal patients</p> </div>	<div data-bbox="1575 284 1953 430" style="border: 1px solid black; padding: 5px;"> <p><b>EAY191 (ComboMATCH)</b></p> </div>

## Legend by Subtype Status

Green = TNBC

Orange = HER2+  
(Any HR status)

Purple =  
HR+ and HER2-

Pink = Cross-  
disease trial

## NCTN Breast Cancer Trials (Open as of 5/15/2026)

Protocol Number	Phase	Protocol Title
<b>A012103</b>	III	OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
<b>A012303</b>	III	ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
<b>CCTG MA.39</b>	III	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
<b>NRG-BR009</b>	III	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score $\leq$ 25 (OFSET)
<b>S2206</b>	III	Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
<b>S2212</b>	III	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
<b>EAY191</b>	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)

This portfolio shows NCTN trials. For information about NCORP trials, please see: <https://ncorp.cancer.gov/find-a-study/>